摘要
肿瘤相关血栓栓塞是恶性肿瘤最重要的并发症,是仅次于肿瘤本身引起患者死亡的第二位原因。血栓形成参与了肿瘤进展、血管生成和转移的机制。抗凝治疗能抑制肿瘤的发生、发展,改善肿瘤患者的预后。低分子肝素(LMWH)有抗肿瘤作用,能延长肿瘤患者的生存时间。LMWH已成为静脉血栓栓塞症患者初始治疗的首选药物。
The most important complication of malignant tumor is tumor correlated thromboembolism, which is also the second reason leading to death besides tumor itself. Thrombosis participate in the mechanisms of vascularization, tumor progression and metastasis. Anticoagulant therapy can improve the prognosis of tumor patients through inhibiting the genesis and development of tumor. Low-molecular-weight Heparin （LMWH） can inhibit tumor, prolong overall survival of tumor patients. LMWH has become the first choice in initial treatment of venous thromboembolism.,
出处
《中国医药指南》
2012年第27期61-64,共4页
Guide of China Medicine
关键词
恶性肿瘤
静脉血栓栓塞
低分子肝素
Malignant tumor
Venous thromboembolism
Low-molecular-weight heparin
